After receiving a standard 10 mCi dose of radioactive iodine, 8 out of 10 people with Graves' disease still had slightly elevated thyroid hormone levels at 6 months, meaning the treatment did not fully shut down their thyroid in most cases.
Claim Context
In patients with Graves' disease treated with a fixed 10 mCi dose of radioactive iodine, persistent subclinical hyperthyroidism at 6 months occurred in 80% of cases, suggesting that thyroid hormone suppression may be incomplete or transient in the majority of patients with this dosing regimen.
“At 6 months, 80% of subjects remained with subclinical hyperthyroidism, 10% experienced worsening hyperthyroidism and 10% had developed permanent hypothyroidism.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled rate of persistent subclinical hyperthyroidism at 6 months after fixed 10 mCi RAI in Graves' disease patients who failed ATD, stratified by baseline thyroid volume and TRAb levels.
A systematic review and meta-analysis of all prospective cohort studies and RCTs reporting subclinical hyperthyroidism (TSH <0.4 mIU/L with normal FT4) at 6 months post-10 mCi RAI in adults with Graves' disease and prior ATD failure, including at least 1200 patients across 20+ studies.
Whether a higher fixed dose (e.g., 15 mCi) reduces the rate of persistent subclinical hyperthyroidism at 6 months compared to 10 mCi in Graves' disease patients.
A double-blind RCT of 150 adults with Graves' disease and failed ATD, randomized to receive either 10 mCi or 15 mCi RAI, with primary outcome of subclinical hyperthyroidism (TSH <0.4 mIU/L and FT4 within normal range) at 6 months, controlling for baseline TRAb and thyroid volume.
The natural history of thyroid function after 10 mCi RAI in Graves' disease, specifically the proportion of patients with persistent subclinical hyperthyroidism at 6 months and its predictors.
A prospective cohort study of 200 adults with Graves' disease treated with 10 mCi RAI, with serial TSH and FT4 measurements at 1, 3, 6, 12, and 24 months, and baseline collection of thyroid volume, TRAb, smoking status, and goiter size.
The prevalence of subclinical hyperthyroidism at a single time point (6 months) after 10 mCi RAI in a population of Graves' disease patients.
A cross-sectional survey of 300 adults with Graves' disease who received 10 mCi RAI at least 6 months prior, measuring current TSH and FT4 levels and collecting retrospective data on baseline characteristics and treatment history.
Anecdotal observations of prolonged subclinical hyperthyroidism after 10 mCi RAI in individual patients.
A case series of 10–20 patients with Graves' disease treated with 10 mCi RAI, documenting individual TSH and FT4 trajectories over 12 months, including unusual responses such as delayed normalization or recurrence.